Cargando…

Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer

BACKGROUND: Finding effective prognostic signatures is of great urgency due to the high risk of recurrence and progression of bladder cancer (BC). Although a lot of genetic alterations are involved in the carcinogenesis, none of them were referred in the current risk group stratifications. In this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Zhao, Chen, Huang, Bai, Jingqiao, Zheng, Yang, Ma, Jianhui, Cai, Xiongwei, Liu, Yu, Zhang, Kaitai, Shou, Jianzhong, Gao, Yanning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141655/
https://www.ncbi.nlm.nih.gov/pubmed/34041036
http://dx.doi.org/10.3389/fonc.2021.674933
_version_ 1783696409518669824
author Cai, Zhao
Chen, Huang
Bai, Jingqiao
Zheng, Yang
Ma, Jianhui
Cai, Xiongwei
Liu, Yu
Zhang, Kaitai
Shou, Jianzhong
Gao, Yanning
author_facet Cai, Zhao
Chen, Huang
Bai, Jingqiao
Zheng, Yang
Ma, Jianhui
Cai, Xiongwei
Liu, Yu
Zhang, Kaitai
Shou, Jianzhong
Gao, Yanning
author_sort Cai, Zhao
collection PubMed
description BACKGROUND: Finding effective prognostic signatures is of great urgency due to the high risk of recurrence and progression of bladder cancer (BC). Although a lot of genetic alterations are involved in the carcinogenesis, none of them were referred in the current risk group stratifications. In this study, we aimed to find significant copy number variations (CNVs) to predict prognosis for BC patients. METHODS: CNVs with high aberration frequencies in BC were explored by array-based comparative genomic hybridization in 65 tumor samples. Candidates were validated in independent groups of BC tumor samples (n=219) and urine samples (n=123). 3D digital PCR was applied for detecting accurate gene copy numbers in BC urine. In order to explore the prognostic value of candidate CNVs, all enrolled patients were followed up for the disease-free survival (DFS). Cox proportional hazards regression analysis was performed to find the independent prognostic factors for DFS. RESULTS: CNVs of CEP63, FOSL2 and PAQR6 with high aberration frequencies (67.7%, 56.9% and 60.0%, respectively) were found in BC tumors. Copy numbers of CEP63, FOSL2 and PAQR6 were gained in 219 tumor samples. CNVs of CEP63 and FOSL2 were correlated with advanced tumor stage and high grade. Retrospective analysis (median follow-up time: 69 months) revealed that CNVs of CEP63 and FOSL2 were independent prognostic factors for DFS of non-muscle-invasive bladder cancer (NMIBC) patients, while CNVs of FOSL2 and PAQR6 were independent prognostic factors for DFS of muscle-invasive bladder cancer (MIBC) patients. Models for predicting DFS were constructed based on CNVs of three genes. Patients with high prognostic indexes tended to have poor DFS. Prognostic index can also help to identify those with worse outcomes among high risk NMIBC patients. Copy number gains of CEP63 and FOSL2 in urine were found to be significantly correlated with poor DFS of NMIBC patients. CONCLUSIONS: CNVs of CEP63, FOSL2 and PAQR6 were capable of predicting DFS and may serve as promising signatures for prognosis of BC.
format Online
Article
Text
id pubmed-8141655
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81416552021-05-25 Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer Cai, Zhao Chen, Huang Bai, Jingqiao Zheng, Yang Ma, Jianhui Cai, Xiongwei Liu, Yu Zhang, Kaitai Shou, Jianzhong Gao, Yanning Front Oncol Oncology BACKGROUND: Finding effective prognostic signatures is of great urgency due to the high risk of recurrence and progression of bladder cancer (BC). Although a lot of genetic alterations are involved in the carcinogenesis, none of them were referred in the current risk group stratifications. In this study, we aimed to find significant copy number variations (CNVs) to predict prognosis for BC patients. METHODS: CNVs with high aberration frequencies in BC were explored by array-based comparative genomic hybridization in 65 tumor samples. Candidates were validated in independent groups of BC tumor samples (n=219) and urine samples (n=123). 3D digital PCR was applied for detecting accurate gene copy numbers in BC urine. In order to explore the prognostic value of candidate CNVs, all enrolled patients were followed up for the disease-free survival (DFS). Cox proportional hazards regression analysis was performed to find the independent prognostic factors for DFS. RESULTS: CNVs of CEP63, FOSL2 and PAQR6 with high aberration frequencies (67.7%, 56.9% and 60.0%, respectively) were found in BC tumors. Copy numbers of CEP63, FOSL2 and PAQR6 were gained in 219 tumor samples. CNVs of CEP63 and FOSL2 were correlated with advanced tumor stage and high grade. Retrospective analysis (median follow-up time: 69 months) revealed that CNVs of CEP63 and FOSL2 were independent prognostic factors for DFS of non-muscle-invasive bladder cancer (NMIBC) patients, while CNVs of FOSL2 and PAQR6 were independent prognostic factors for DFS of muscle-invasive bladder cancer (MIBC) patients. Models for predicting DFS were constructed based on CNVs of three genes. Patients with high prognostic indexes tended to have poor DFS. Prognostic index can also help to identify those with worse outcomes among high risk NMIBC patients. Copy number gains of CEP63 and FOSL2 in urine were found to be significantly correlated with poor DFS of NMIBC patients. CONCLUSIONS: CNVs of CEP63, FOSL2 and PAQR6 were capable of predicting DFS and may serve as promising signatures for prognosis of BC. Frontiers Media S.A. 2021-05-10 /pmc/articles/PMC8141655/ /pubmed/34041036 http://dx.doi.org/10.3389/fonc.2021.674933 Text en Copyright © 2021 Cai, Chen, Bai, Zheng, Ma, Cai, Liu, Zhang, Shou and Gao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cai, Zhao
Chen, Huang
Bai, Jingqiao
Zheng, Yang
Ma, Jianhui
Cai, Xiongwei
Liu, Yu
Zhang, Kaitai
Shou, Jianzhong
Gao, Yanning
Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer
title Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer
title_full Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer
title_fullStr Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer
title_full_unstemmed Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer
title_short Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer
title_sort copy number variations of cep63, fosl2 and paqr6 serve as novel signatures for the prognosis of bladder cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141655/
https://www.ncbi.nlm.nih.gov/pubmed/34041036
http://dx.doi.org/10.3389/fonc.2021.674933
work_keys_str_mv AT caizhao copynumbervariationsofcep63fosl2andpaqr6serveasnovelsignaturesfortheprognosisofbladdercancer
AT chenhuang copynumbervariationsofcep63fosl2andpaqr6serveasnovelsignaturesfortheprognosisofbladdercancer
AT baijingqiao copynumbervariationsofcep63fosl2andpaqr6serveasnovelsignaturesfortheprognosisofbladdercancer
AT zhengyang copynumbervariationsofcep63fosl2andpaqr6serveasnovelsignaturesfortheprognosisofbladdercancer
AT majianhui copynumbervariationsofcep63fosl2andpaqr6serveasnovelsignaturesfortheprognosisofbladdercancer
AT caixiongwei copynumbervariationsofcep63fosl2andpaqr6serveasnovelsignaturesfortheprognosisofbladdercancer
AT liuyu copynumbervariationsofcep63fosl2andpaqr6serveasnovelsignaturesfortheprognosisofbladdercancer
AT zhangkaitai copynumbervariationsofcep63fosl2andpaqr6serveasnovelsignaturesfortheprognosisofbladdercancer
AT shoujianzhong copynumbervariationsofcep63fosl2andpaqr6serveasnovelsignaturesfortheprognosisofbladdercancer
AT gaoyanning copynumbervariationsofcep63fosl2andpaqr6serveasnovelsignaturesfortheprognosisofbladdercancer